Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01540071 · ClinicalTrials.gov registry record · Phase 2
Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer
A Phase 2 study of Castration-resistant Prostate Cancer, sponsored by Io Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
- 1
- Study location
NCT01540071 is a Phase 2 study of Castration-resistant Prostate Cancer that has completed, run by Io Therapeutics. The registered enrollment target is 38 participants, below the 215-participant average among 15 other Castration-resistant Prostate Cancer trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01540071, a Phase 2 study of Castration-resistant Prostate Cancer, has completed, sponsored by Io Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is to evaluate the benefits of investigational drug, NRX 194204 in slowing down/stopping/reversing progression of the castration resistant and taxane resistant prostate cancer.
Conditions Studied
Interventions
- DRUG NRX 194204
Study Locations (1)
California
- Lalita Pandit, MD - Fountain Valley
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2011-08 |
| Est. Completion | 2015-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01540071
The ClinicalTrials.gov registry entry for NCT01540071 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 215-participant average among 15 other Castration-resistant Prostate Cancer trials with a reported enrollment target (82% lower). The listed sponsor is Io Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Castration-resistant Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which NRX 194204 is the first listed.
NCT01540071 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01540071 about?
NCT01540071 is a clinical study titled "Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer". This study is to evaluate the benefits of investigational drug, NRX 194204 in slowing down/stopping/reversing progression of the castration resistant and taxane resistant prostate cancer.
What is the current status of trial NCT01540071?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2011-08. Estimated completion is 2015-12.
What conditions does trial NCT01540071 study?
This clinical trial studies the following conditions: Castration-resistant Prostate Cancer.
What interventions are being tested in trial NCT01540071?
The interventions under investigation include: NRX 194204 (DRUG).
Who is sponsoring clinical trial NCT01540071?
This trial is sponsored by Io Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01540071 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Castration-resistant Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer
RECRUITING · Phase 2
-
Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer
RECRUITING · Phase 2
-
Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
RECRUITING · Phase 2
-
pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer
ACTIVE NOT RECRUITING · Phase 2
-
I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).
COMPLETED · Phase 2
-
ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.